The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis

Psoriasis is a frequent, inflammatory skin disease characterized by keratinocyte hyperproliferation and a disease-related infiltration of immune cells. Here, we identified a novel proinflammatory signaling pathway driven by cyclin-dependent kinase 4 (CDK4) and CDK6 and the methyltransferase EZH2 as...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Müller, Anne (Verfasst von) , Dickmanns, Antje (Verfasst von) , Resch, Claudia (Verfasst von) , Schäkel, Knut (Verfasst von) , Hailfinger, Stephan (Verfasst von) , Dobbelstein, Matthias (Verfasst von) , Schulze-Osthoff, Klaus (Verfasst von) , Kramer, Daniela (Verfasst von)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: July 23, 2020
In: The journal of clinical investigation
Year: 2020, Jahrgang: 130, Heft: 11, Pages: 5765-5781
ISSN:1558-8238
DOI:10.1172/JCI134217
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1172/JCI134217
Verlag, lizenzpflichtig, Volltext: https://www.jci.org/articles/view/134217
Volltext
Verfasserangaben:Anne Müller, Antje Dickmanns, Claudia Resch, Knut Schäkel, Stephan Hailfinger, Matthias Dobbelstein, Klaus Schulze-Osthoff, and Daniela Kramer

MARC

LEADER 00000caa a2200000 c 4500
001 1756964017
003 DE-627
005 20230426114209.0
007 cr uuu---uuuuu
008 210503s2020 xx |||||o 00| ||eng c
024 7 |a 10.1172/JCI134217  |2 doi 
035 |a (DE-627)1756964017 
035 |a (DE-599)KXP1756964017 
035 |a (OCoLC)1341407745 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Müller, Anne  |d 1992-  |e VerfasserIn  |0 (DE-588)1221631624  |0 (DE-627)1738902889  |4 aut 
245 1 4 |a The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis  |c Anne Müller, Antje Dickmanns, Claudia Resch, Knut Schäkel, Stephan Hailfinger, Matthias Dobbelstein, Klaus Schulze-Osthoff, and Daniela Kramer 
264 1 |c July 23, 2020 
300 |a 17 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 03.05.2021 
520 |a Psoriasis is a frequent, inflammatory skin disease characterized by keratinocyte hyperproliferation and a disease-related infiltration of immune cells. Here, we identified a novel proinflammatory signaling pathway driven by cyclin-dependent kinase 4 (CDK4) and CDK6 and the methyltransferase EZH2 as a valid target for psoriasis therapy. Delineation of the pathway revealed that CDK4/6 phosphorylated EZH2 in keratinocytes, thereby triggering a methylation-induced activation of STAT3. Subsequently, active STAT3 resulted in the induction of IκBζ, which is a key proinflammatory transcription factor required for cytokine synthesis in psoriasis. Pharmacological or genetic inhibition of CDK4/6 or EZH2 abrogated psoriasis-related proinflammatory gene expression by suppressing IκBζ induction in keratinocytes. Importantly, topical application of CDK4/6 or EZH2 inhibitors on the skin was sufficient to fully prevent the development of psoriasis in various mouse models by suppressing STAT3-mediated IκBζ expression. Moreover, we found a hyperactivation of the CDK4/6-EZH2 pathway in human and mouse psoriatic skin lesions. Thus, this study not only identifies a novel psoriasis-relevant proinflammatory pathway, but also proposes the repurposing of CDK4/6 or EZH2 inhibitors as a new therapeutic option for patients with psoriasis. 
700 1 |a Dickmanns, Antje  |e VerfasserIn  |4 aut 
700 1 |a Resch, Claudia  |e VerfasserIn  |4 aut 
700 1 |a Schäkel, Knut  |e VerfasserIn  |0 (DE-588)1032757418  |0 (DE-627)739272896  |0 (DE-576)251064476  |4 aut 
700 1 |a Hailfinger, Stephan  |e VerfasserIn  |4 aut 
700 1 |a Dobbelstein, Matthias  |e VerfasserIn  |4 aut 
700 1 |a Schulze-Osthoff, Klaus  |e VerfasserIn  |4 aut 
700 1 |a Kramer, Daniela  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t The journal of clinical investigation  |d Ann Arbor, Mich. : ASCJ, 1924  |g 130(2020), 11, Seite 5765-5781  |h Online-Ressource  |w (DE-627)316004677  |w (DE-600)2018375-6  |w (DE-576)094950423  |x 1558-8238  |7 nnas  |a The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis 
773 1 8 |g volume:130  |g year:2020  |g number:11  |g pages:5765-5781  |g extent:17  |a The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis 
856 4 0 |u https://doi.org/10.1172/JCI134217  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.jci.org/articles/view/134217  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20210503 
993 |a Article 
994 |a 2020 
998 |g 1032757418  |a Schäkel, Knut  |m 1032757418:Schäkel, Knut  |d 910000  |d 911300  |e 910000PS1032757418  |e 911300PS1032757418  |k 0/910000/  |k 1/910000/911300/  |p 4 
999 |a KXP-PPN1756964017  |e 392155182X 
BIB |a Y 
SER |a journal 
JSO |a {"title":[{"title_sort":"CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis","title":"The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis"}],"language":["eng"],"recId":"1756964017","type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"July 23, 2020"}],"note":["Gesehen am 03.05.2021"],"id":{"eki":["1756964017"],"doi":["10.1172/JCI134217"]},"physDesc":[{"extent":"17 S."}],"name":{"displayForm":["Anne Müller, Antje Dickmanns, Claudia Resch, Knut Schäkel, Stephan Hailfinger, Matthias Dobbelstein, Klaus Schulze-Osthoff, and Daniela Kramer"]},"person":[{"given":"Anne","role":"aut","family":"Müller","display":"Müller, Anne"},{"role":"aut","family":"Dickmanns","display":"Dickmanns, Antje","given":"Antje"},{"given":"Claudia","role":"aut","family":"Resch","display":"Resch, Claudia"},{"display":"Schäkel, Knut","family":"Schäkel","role":"aut","given":"Knut"},{"given":"Stephan","role":"aut","family":"Hailfinger","display":"Hailfinger, Stephan"},{"display":"Dobbelstein, Matthias","family":"Dobbelstein","role":"aut","given":"Matthias"},{"given":"Klaus","display":"Schulze-Osthoff, Klaus","family":"Schulze-Osthoff","role":"aut"},{"display":"Kramer, Daniela","family":"Kramer","role":"aut","given":"Daniela"}],"relHost":[{"id":{"eki":["316004677"],"issn":["1558-8238"],"zdb":["2018375-6"]},"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 25.01.2022","Fortsetzung der Druck-Ausgabe"],"pubHistory":["1.1924/25 -"],"physDesc":[{"extent":"Online-Ressource"}],"titleAlt":[{"title":"JCI"}],"part":{"extent":"17","year":"2020","issue":"11","volume":"130","text":"130(2020), 11, Seite 5765-5781","pages":"5765-5781"},"language":["eng"],"title":[{"title_sort":"journal of clinical investigation","title":"The journal of clinical investigation","subtitle":"JCI ; the publication of the American Society for Clinical Investigation"}],"disp":"The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasisThe journal of clinical investigation","recId":"316004677","corporate":[{"role":"isb","display":"American Society for Clinical Investigation"}],"origin":[{"dateIssuedDisp":"1924-","dateIssuedKey":"1924","publisherPlace":"Ann Arbor, Mich.","publisher":"ASCJ"}]}]} 
SRT |a MUELLERANNCDK46EZH2P2320